The global Opioid Induced Constipation (OIC) Drugs market was valued at US$ 2890 million in 2025 and is anticipated to reach US$ 3942 million by 2032, at a CAGR of 4.6% from 2026 to 2032.

Opioid Induced Constipation (OIC) Drugs Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Opioid Induced Constipation (OIC) Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Opioid Induced Constipation (OIC) refers to constipation symptoms induced by the prolonged use of opioid analgesics such as morphine, fentanyl, and oxycodone. This side effect is particularly common among chronic pain patients and significantly impacts their quality of life. To address this issue, various OIC drugs have been developed, including peripheral µ-opioid receptor antagonists (PAMORAs), prokinetic agents, osmotic or bulk-forming laxatives, stimulant laxatives, and combination therapies. These drugs alleviate or treat constipation symptoms caused by opioid use through different mechanisms of action.In 2024, global Opioid Induced Constipation (OIC) Drugs production reached approximately 277.5 m units , with an average global market price of around US$ 10 perunit.The average gross profit margin of this product is 37%.

The accelerating global aging process and the increasing number of chronic disease patients, especially cancer patients and those undergoing long-term analgesic treatment, have led to a rise in opioid use, thereby increasing the incidence of OIC. Moreover, the growing attention of medical institutions to patients' quality of life has driven the demand for OIC treatment drugs. The development and launch of new drugs, such as Naldemedine, have introduced new treatment options to the market, further promoting its development.

Despite the growing market demand, the high cost of OIC drugs remains a major challenge for patients and healthcare systems. Additionally, some drugs may have side effects, such as diarrhea and nausea, affecting patient compliance. In certain regions, especially in China, treatment options for OIC are limited, primarily relying on adjusting opioid doses or using traditional laxatives, which restricts further market development.

As patients place more emphasis on quality of life, medical institutions' awareness of OIC has increased, driving the use of OIC drugs. Particularly in cancer treatment and chronic pain management, the demand for OIC drugs continues to grow. Furthermore, the increasing demand for personalized treatment has driven the research and application of OIC drugs tailored to different patient groups.

The production of OIC drugs involves various raw materials, including active pharmaceutical ingredients (APIs), excipients, and packaging materials. The production of APIs requires high-purity chemical raw materials and complex synthesis processes to ensure the efficacy and safety of the drugs. Excipients, such as fillers and stabilizers, influence the stability of the drugs and the patient's experience. The choice of packaging materials relates to the storage and transportation conditions of the drugs. Therefore, the quality and supply stability of raw materials are crucial to the production of OIC drugs.

This report delivers a comprehensive overview of the global Opioid Induced Constipation (OIC) Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Opioid Induced Constipation (OIC) Drugs. The Opioid Induced Constipation (OIC) Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Opioid Induced Constipation (OIC) Drugs market comprehensively. Regional market sizes by Type, by Application, Route of Administration, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Opioid Induced Constipation (OIC) Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Opioid Induced Constipation (OIC) Drugs Market Report

Report Metric	Details
Report Name	Opioid Induced Constipation (OIC) Drugs Market
Accounted market size in 2025	US$ 2890 million
Forecasted market size in 2032	US$ 3942 million
CAGR	4.6%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Lubiprostone Methyl Naltrexone Bromide Naldemedine Alvimopan Others Segment Route of Administration Oral Formulations Injectable Formulations Suppositories / Enemas Other Segment Chemical Class Peripheral µ-opioid Receptor Antagonists, Prokinetic Agents Bulk-forming Laxatives
by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi, Bausch Health, Zentiva, Orifarm A/S, Viatris, Endo International, Zhengdatianqing
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, Route of Administration, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Opioid Induced Constipation (OIC) Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Opioid Induced Constipation (OIC) Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Opioid Induced Constipation (OIC) Drugs Market growing?

Ans: The Opioid Induced Constipation (OIC) Drugs Market witnessing a CAGR of 4.6% during the forecast period 2026-2032.

What is the Opioid Induced Constipation (OIC) Drugs Market size in 2032?

Ans: The Opioid Induced Constipation (OIC) Drugs Market size in 2032 will be US$ 3942 million.

Who are the main players in the Opioid Induced Constipation (OIC) Drugs Market report?

Ans: The main players in the Opioid Induced Constipation (OIC) Drugs Market are Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi, Bausch Health, Zentiva, Orifarm A/S, Viatris, Endo International, Zhengdatianqing

What are the Application segmentation covered in the Opioid Induced Constipation (OIC) Drugs Market report?

Ans: The Applications covered in the Opioid Induced Constipation (OIC) Drugs Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Opioid Induced Constipation (OIC) Drugs Market report?

Ans: The Types covered in the Opioid Induced Constipation (OIC) Drugs Market report are Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Others, Segment Route of Administration, Oral Formulations, Injectable Formulations, Suppositories / Enemas, Other, Segment Chemical Class, Peripheral µ-opioid Receptor Antagonists,, Prokinetic Agents, Bulk-forming Laxatives

1 Opioid Induced Constipation (OIC) Drugs Market Overview

1.1 Product Definition

1.2 Opioid Induced Constipation (OIC) Drugs by Type

1.2.1 Global Opioid Induced Constipation (OIC) Drugs Market Value by Type: 2025 vs 2032

1.2.2 Lubiprostone

1.2.3 Methyl Naltrexone Bromide

1.2.4 Naldemedine

1.2.5 Alvimopan

1.2.6 Others

1.3 Opioid Induced Constipation (OIC) Drugs Route of Administration

1.3.1 Global Opioid Induced Constipation (OIC) Drugs Market Value Route of Administration: 2025 vs 2032

1.3.2 Oral Formulations

1.3.3 Injectable Formulations

1.3.4 Suppositories / Enemas

1.3.5 Other

1.4 Opioid Induced Constipation (OIC) Drugs Chemical Class

1.4.1 Global Opioid Induced Constipation (OIC) Drugs Market Value Chemical Class: 2025 vs 2032

1.4.2 Peripheral µ-opioid Receptor Antagonists,

1.4.3 Prokinetic Agents

1.4.4 Bulk-forming Laxatives

1.4.5 Other

1.5 Opioid Induced Constipation (OIC) Drugs by Application

1.5.1 Global Opioid Induced Constipation (OIC) Drugs Market Value by Application: 2025 vs 2032

1.5.2 Hospital Pharmacies

1.5.3 Retail Pharmacies

1.5.4 Online Pharmacies

1.6 Global Opioid Induced Constipation (OIC) Drugs Market Size Estimates and Forecasts

1.6.1 Global Opioid Induced Constipation (OIC) Drugs Revenue 2021–2032

1.6.2 Global Opioid Induced Constipation (OIC) Drugs Sales 2021–2032

1.6.3 Global Opioid Induced Constipation (OIC) Drugs Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 Opioid Induced Constipation (OIC) Drugs Market Competition by Manufacturers

2.1 Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Manufacturers (2021–2026)

2.2 Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Opioid Induced Constipation (OIC) Drugs Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Opioid Induced Constipation (OIC) Drugs, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Opioid Induced Constipation (OIC) Drugs, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Opioid Induced Constipation (OIC) Drugs, Product Types and Applications

2.7 Global Key Manufacturers of Opioid Induced Constipation (OIC) Drugs, Date of Entry into the Industry

2.8 Global Opioid Induced Constipation (OIC) Drugs Market Competitive Situation and Trends

2.8.1 Global Opioid Induced Constipation (OIC) Drugs Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Opioid Induced Constipation (OIC) Drugs Players Market Share by Revenue

2.8.3 Global Opioid Induced Constipation (OIC) Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Opioid Induced Constipation (OIC) Drugs Market Scenario by Region

3.1 Global Opioid Induced Constipation (OIC) Drugs Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Opioid Induced Constipation (OIC) Drugs Sales by Region: 2021–2032

3.2.1 Global Opioid Induced Constipation (OIC) Drugs Sales by Region: 2021–2026

3.2.2 Global Opioid Induced Constipation (OIC) Drugs Sales by Region: 2027–2032

3.3 Global Opioid Induced Constipation (OIC) Drugs Revenue by Region: 2021–2032

3.3.1 Global Opioid Induced Constipation (OIC) Drugs Revenue by Region: 2021–2026

3.3.2 Global Opioid Induced Constipation (OIC) Drugs Revenue by Region: 2027–2032

3.4 North America Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Country

3.4.1 North America Opioid Induced Constipation (OIC) Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Opioid Induced Constipation (OIC) Drugs Sales by Country (2021–2032)

3.4.3 North America Opioid Induced Constipation (OIC) Drugs Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Country

3.5.1 Europe Opioid Induced Constipation (OIC) Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Opioid Induced Constipation (OIC) Drugs Sales by Country (2021–2032)

3.5.3 Europe Opioid Induced Constipation (OIC) Drugs Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Opioid Induced Constipation (OIC) Drugs Sales by Region (2021–2032)

3.6.3 Asia Pacific Opioid Induced Constipation (OIC) Drugs Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Country

3.7.1 Latin America Opioid Induced Constipation (OIC) Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Opioid Induced Constipation (OIC) Drugs Sales by Country (2021–2032)

3.7.3 Latin America Opioid Induced Constipation (OIC) Drugs Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Opioid Induced Constipation (OIC) Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Opioid Induced Constipation (OIC) Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Opioid Induced Constipation (OIC) Drugs Sales by Country (2021–2032)

3.8.3 Middle East and Africa Opioid Induced Constipation (OIC) Drugs Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Opioid Induced Constipation (OIC) Drugs Sales by Type (2021–2032)

4.1.1 Global Opioid Induced Constipation (OIC) Drugs Sales by Type (2021–2026)

4.1.2 Global Opioid Induced Constipation (OIC) Drugs Sales by Type (2027–2032)

4.1.3 Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Type (2021–2032)

4.2 Global Opioid Induced Constipation (OIC) Drugs Revenue by Type (2021–2032)

4.2.1 Global Opioid Induced Constipation (OIC) Drugs Revenue by Type (2021–2026)

4.2.2 Global Opioid Induced Constipation (OIC) Drugs Revenue by Type (2027–2032)

4.2.3 Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Type (2021–2032)

4.3 Global Opioid Induced Constipation (OIC) Drugs Price by Type (2021–2032)

5 Segment by Application

5.1 Global Opioid Induced Constipation (OIC) Drugs Sales by Application (2021–2032)

5.1.1 Global Opioid Induced Constipation (OIC) Drugs Sales by Application (2021–2026)

5.1.2 Global Opioid Induced Constipation (OIC) Drugs Sales by Application (2027–2032)

5.1.3 Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Application (2021–2032)

5.2 Global Opioid Induced Constipation (OIC) Drugs Revenue by Application (2021–2032)

5.2.1 Global Opioid Induced Constipation (OIC) Drugs Revenue by Application (2021–2026)

5.2.2 Global Opioid Induced Constipation (OIC) Drugs Revenue by Application (2027–2032)

5.2.3 Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Application (2021–2032)

5.3 Global Opioid Induced Constipation (OIC) Drugs Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Takeda Pharmaceuticals

6.1.1 Takeda Pharmaceuticals Company Information

6.1.2 Takeda Pharmaceuticals Description and Business Overview

6.1.3 Takeda Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Takeda Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.1.5 Takeda Pharmaceuticals Recent Developments/Updates

6.2 Bayer

6.2.1 Bayer Company Information

6.2.2 Bayer Description and Business Overview

6.2.3 Bayer Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Bayer Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.2.5 Bayer Recent Developments/Updates

6.3 Sanofi

6.3.1 Sanofi Company Information

6.3.2 Sanofi Description and Business Overview

6.3.3 Sanofi Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Sanofi Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.3.5 Sanofi Recent Developments/Updates

6.4 Mallinckrodt

6.4.1 Mallinckrodt Company Information

6.4.2 Mallinckrodt Description and Business Overview

6.4.3 Mallinckrodt Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Mallinckrodt Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.4.5 Mallinckrodt Recent Developments/Updates

6.5 Salix (Bausch Health)

6.5.1 Salix (Bausch Health) Company Information

6.5.2 Salix (Bausch Health) Description and Business Overview

6.5.3 Salix (Bausch Health) Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Salix (Bausch Health) Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.5.5 Salix (Bausch Health) Recent Developments/Updates

6.6 AstraZeneca

6.6.1 AstraZeneca Company Information

6.6.2 AstraZeneca Description and Business Overview

6.6.3 AstraZeneca Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 AstraZeneca Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.6.5 AstraZeneca Recent Developments/Updates

6.7 Progenics Pharmaceuticals

6.7.1 Progenics Pharmaceuticals Company Information

6.7.2 Progenics Pharmaceuticals Description and Business Overview

6.7.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.7.5 Progenics Pharmaceuticals Recent Developments/Updates

6.8 Purdue Pharm

6.8.1 Purdue Pharm Company Information

6.8.2 Purdue Pharm Description and Business Overview

6.8.3 Purdue Pharm Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Purdue Pharm Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.8.5 Purdue Pharm Recent Developments/Updates

6.9 Nektar Therapeutics

6.9.1 Nektar Therapeutics Company Information

6.9.2 Nektar Therapeutics Description and Business Overview

6.9.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.9.5 Nektar Therapeutics Recent Developments/Updates

6.10 Daiichi Sankyo

6.10.1 Daiichi Sankyo Company Information

6.10.2 Daiichi Sankyo Description and Business Overview

6.10.3 Daiichi Sankyo Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Daiichi Sankyo Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.10.5 Daiichi Sankyo Recent Developments/Updates

6.11 Prestige

6.11.1 Prestige Company Information

6.11.2 Prestige Description and Business Overview

6.11.3 Prestige Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Prestige Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.11.5 Prestige Recent Developments/Updates

6.12 GSK

6.12.1 GSK Company Information

6.12.2 GSK Description and Business Overview

6.12.3 GSK Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.12.4 GSK Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.12.5 GSK Recent Developments/Updates

6.13 Shionogi

6.13.1 Shionogi Company Information

6.13.2 Shionogi Description and Business Overview

6.13.3 Shionogi Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.13.4 Shionogi Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.13.5 Shionogi Recent Developments/Updates

6.14 Bausch Health

6.14.1 Bausch Health Company Information

6.14.2 Bausch Health Description and Business Overview

6.14.3 Bausch Health Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.14.4 Bausch Health Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.14.5 Bausch Health Recent Developments/Updates

6.15 Zentiva

6.15.1 Zentiva Company Information

6.15.2 Zentiva Description and Business Overview

6.15.3 Zentiva Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.15.4 Zentiva Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.15.5 Zentiva Recent Developments/Updates

6.16 Orifarm A/S

6.16.1 Orifarm A/S Company Information

6.16.2 Orifarm A/S Description and Business Overview

6.16.3 Orifarm A/S Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.16.4 Orifarm A/S Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.16.5 Orifarm A/S Recent Developments/Updates

6.17 Viatris

6.17.1 Viatris Company Information

6.17.2 Viatris Description and Business Overview

6.17.3 Viatris Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.17.4 Viatris Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.17.5 Viatris Recent Developments/Updates

6.18 Endo International

6.18.1 Endo International Company Information

6.18.2 Endo International Description and Business Overview

6.18.3 Endo International Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.18.4 Endo International Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.18.5 Endo International Recent Developments/Updates

6.19 Zhengdatianqing

6.19.1 Zhengdatianqing Company Information

6.19.2 Zhengdatianqing Description and Business Overview

6.19.3 Zhengdatianqing Opioid Induced Constipation (OIC) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.19.4 Zhengdatianqing Opioid Induced Constipation (OIC) Drugs Product Portfolio

6.19.5 Zhengdatianqing Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Opioid Induced Constipation (OIC) Drugs Industry Chain Analysis

7.2 Opioid Induced Constipation (OIC) Drugs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Opioid Induced Constipation (OIC) Drugs Production Mode & Process Analysis

7.4 Opioid Induced Constipation (OIC) Drugs Sales and Marketing

7.4.1 Opioid Induced Constipation (OIC) Drugs Sales Channels

7.4.2 Opioid Induced Constipation (OIC) Drugs Distributors

7.5 Opioid Induced Constipation (OIC) Drugs Customer Analysis

8 Opioid Induced Constipation (OIC) Drugs Market Dynamics

8.1 Opioid Induced Constipation (OIC) Drugs Industry Trends

8.2 Opioid Induced Constipation (OIC) Drugs Market Drivers

8.3 Opioid Induced Constipation (OIC) Drugs Market Challenges

8.4 Opioid Induced Constipation (OIC) Drugs Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Shionogi

Nektar Therapeutics

Bausch Health

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt plc

Salix (Bausch Health)

Astrazeneca plc

Progenics Pharmaceuticals

List of Tables

Table 1. Global Opioid Induced Constipation (OIC) Drugs Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Opioid Induced Constipation (OIC) Drugs Market Value Route of Administration (US$ Million), 2025 vs 2032

Table 3. Global Opioid Induced Constipation (OIC) Drugs Market Value Chemical Class (US$ Million), 2025 vs 2032

Table 4. Global Opioid Induced Constipation (OIC) Drugs Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global Opioid Induced Constipation (OIC) Drugs Market Competitive Situation by Manufacturers in 2025

Table 6. Global Opioid Induced Constipation (OIC) Drugs Sales (K Dose) of Key Manufacturers (2021–2026)

Table 7. Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Manufacturers (2021–2026)

Table 8. Global Opioid Induced Constipation (OIC) Drugs Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global Opioid Induced Constipation (OIC) Drugs Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market Opioid Induced Constipation (OIC) Drugs Average Price (USD/Dose) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of Opioid Induced Constipation (OIC) Drugs, Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of Opioid Induced Constipation (OIC) Drugs, Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of Opioid Induced Constipation (OIC) Drugs, Product Types and Applications

Table 14. Global Key Manufacturers of Opioid Induced Constipation (OIC) Drugs, Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global Opioid Induced Constipation (OIC) Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Opioid Induced Constipation (OIC) Drugs Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global Opioid Induced Constipation (OIC) Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global Opioid Induced Constipation (OIC) Drugs Sales by Region (K Dose), 2021–2026

Table 20. Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Region (2021–2026)

Table 21. Global Opioid Induced Constipation (OIC) Drugs Sales by Region (K Dose), 2027–2032

Table 22. Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Region (2027–2032)

Table 23. Global Opioid Induced Constipation (OIC) Drugs Revenue by Region (US$ Million), 2021–2026

Table 24. Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Region (2021–2026)

Table 25. Global Opioid Induced Constipation (OIC) Drugs Revenue by Region (US$ Million), 2027–2032

Table 26. Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Region (2027–2032)

Table 27. North America Opioid Induced Constipation (OIC) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America Opioid Induced Constipation (OIC) Drugs Sales by Country (K Dose), 2021–2026

Table 29. North America Opioid Induced Constipation (OIC) Drugs Sales by Country (K Dose), 2027–2032

Table 30. North America Opioid Induced Constipation (OIC) Drugs Revenue by Country (US$ Million), 2021–2026

Table 31. North America Opioid Induced Constipation (OIC) Drugs Revenue by Country (US$ Million), 2027–2032

Table 32. Europe Opioid Induced Constipation (OIC) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe Opioid Induced Constipation (OIC) Drugs Sales by Country (K Dose), 2021–2026

Table 34. Europe Opioid Induced Constipation (OIC) Drugs Sales by Country (K Dose), 2027–2032

Table 35. Europe Opioid Induced Constipation (OIC) Drugs Revenue by Country (US$ Million), 2021–2026

Table 36. Europe Opioid Induced Constipation (OIC) Drugs Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific Opioid Induced Constipation (OIC) Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific Opioid Induced Constipation (OIC) Drugs Sales by Region (K Dose), 2021–2026

Table 39. Asia Pacific Opioid Induced Constipation (OIC) Drugs Sales by Region (K Dose), 2027–2032

Table 40. Asia Pacific Opioid Induced Constipation (OIC) Drugs Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific Opioid Induced Constipation (OIC) Drugs Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America Opioid Induced Constipation (OIC) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America Opioid Induced Constipation (OIC) Drugs Sales by Country (K Dose), 2021–2026

Table 44. Latin America Opioid Induced Constipation (OIC) Drugs Sales by Country (K Dose), 2027–2032

Table 45. Latin America Opioid Induced Constipation (OIC) Drugs Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America Opioid Induced Constipation (OIC) Drugs Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa Opioid Induced Constipation (OIC) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa Opioid Induced Constipation (OIC) Drugs Sales by Country (K Dose), 2021–2026

Table 49. Middle East and Africa Opioid Induced Constipation (OIC) Drugs Sales by Country (K Dose), 2027–2032

Table 50. Middle East and Africa Opioid Induced Constipation (OIC) Drugs Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa Opioid Induced Constipation (OIC) Drugs Revenue by Country (US$ Million), 2027–2032

Table 52. Global Opioid Induced Constipation (OIC) Drugs Sales (K Dose) by Type (2021–2026)

Table 53. Global Opioid Induced Constipation (OIC) Drugs Sales (K Dose) by Type (2027–2032)

Table 54. Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Type (2021–2026)

Table 55. Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Type (2027–2032)

Table 56. Global Opioid Induced Constipation (OIC) Drugs Revenue (US$ Million) by Type (2021–2026)

Table 57. Global Opioid Induced Constipation (OIC) Drugs Revenue (US$ Million) by Type (2027–2032)

Table 58. Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Type (2021–2026)

Table 59. Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Type (2027–2032)

Table 60. Global Opioid Induced Constipation (OIC) Drugs Price (USD/Dose) by Type (2021–2026)

Table 61. Global Opioid Induced Constipation (OIC) Drugs Price (USD/Dose) by Type (2027–2032)

Table 62. Global Opioid Induced Constipation (OIC) Drugs Sales (K Dose) by Application (2021–2026)

Table 63. Global Opioid Induced Constipation (OIC) Drugs Sales (K Dose) by Application (2027–2032)

Table 64. Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Application (2021–2026)

Table 65. Global Opioid Induced Constipation (OIC) Drugs Sales Market Share by Application (2027–2032)

Table 66. Global Opioid Induced Constipation (OIC) Drugs Revenue (US$ Million) by Application (2021–2026)

Table 67. Global Opioid Induced Constipation (OIC) Drugs Revenue (US$ Million) by Application (2027–2032)

Table 68. Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Application (2021–2026)

Table 69. Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Application (2027–2032)

Table 70. Global Opioid Induced Constipation (OIC) Drugs Price (USD/Dose) by Application (2021–2026)

Table 71. Global Opioid Induced Constipation (OIC) Drugs Price (USD/Dose) by Application (2027–2032)

Table 72. Takeda Pharmaceuticals Company Information

Table 73. Takeda Pharmaceuticals Description and Business Overview

Table 74. Takeda Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 75. Takeda Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product

Table 76. Takeda Pharmaceuticals Recent Developments/Updates

Table 77. Bayer Company Information

Table 78. Bayer Description and Business Overview

Table 79. Bayer Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 80. Bayer Opioid Induced Constipation (OIC) Drugs Product

Table 81. Bayer Recent Developments/Updates

Table 82. Sanofi Company Information

Table 83. Sanofi Description and Business Overview

Table 84. Sanofi Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 85. Sanofi Opioid Induced Constipation (OIC) Drugs Product

Table 86. Sanofi Recent Developments/Updates

Table 87. Mallinckrodt Company Information

Table 88. Mallinckrodt Description and Business Overview

Table 89. Mallinckrodt Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 90. Mallinckrodt Opioid Induced Constipation (OIC) Drugs Product

Table 91. Mallinckrodt Recent Developments/Updates

Table 92. Salix (Bausch Health) Company Information

Table 93. Salix (Bausch Health) Description and Business Overview

Table 94. Salix (Bausch Health) Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 95. Salix (Bausch Health) Opioid Induced Constipation (OIC) Drugs Product

Table 96. Salix (Bausch Health) Recent Developments/Updates

Table 97. AstraZeneca Company Information

Table 98. AstraZeneca Description and Business Overview

Table 99. AstraZeneca Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 100. AstraZeneca Opioid Induced Constipation (OIC) Drugs Product

Table 101. AstraZeneca Recent Developments/Updates

Table 102. Progenics Pharmaceuticals Company Information

Table 103. Progenics Pharmaceuticals Description and Business Overview

Table 104. Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 105. Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product

Table 106. Progenics Pharmaceuticals Recent Developments/Updates

Table 107. Purdue Pharm Company Information

Table 108. Purdue Pharm Description and Business Overview

Table 109. Purdue Pharm Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 110. Purdue Pharm Opioid Induced Constipation (OIC) Drugs Product

Table 111. Purdue Pharm Recent Developments/Updates

Table 112. Nektar Therapeutics Company Information

Table 113. Nektar Therapeutics Description and Business Overview

Table 114. Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 115. Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Product

Table 116. Nektar Therapeutics Recent Developments/Updates

Table 117. Daiichi Sankyo Company Information

Table 118. Daiichi Sankyo Description and Business Overview

Table 119. Daiichi Sankyo Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 120. Daiichi Sankyo Opioid Induced Constipation (OIC) Drugs Product

Table 121. Daiichi Sankyo Recent Developments/Updates

Table 122. Prestige Company Information

Table 123. Prestige Description and Business Overview

Table 124. Prestige Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 125. Prestige Opioid Induced Constipation (OIC) Drugs Product

Table 126. Prestige Recent Developments/Updates

Table 127. GSK Company Information

Table 128. GSK Description and Business Overview

Table 129. GSK Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 130. GSK Opioid Induced Constipation (OIC) Drugs Product

Table 131. GSK Recent Developments/Updates

Table 132. Shionogi Company Information

Table 133. Shionogi Description and Business Overview

Table 134. Shionogi Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 135. Shionogi Opioid Induced Constipation (OIC) Drugs Product

Table 136. Shionogi Recent Developments/Updates

Table 137. Bausch Health Company Information

Table 138. Bausch Health Description and Business Overview

Table 139. Bausch Health Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 140. Bausch Health Opioid Induced Constipation (OIC) Drugs Product

Table 141. Bausch Health Recent Developments/Updates

Table 142. Zentiva Company Information

Table 143. Zentiva Description and Business Overview

Table 144. Zentiva Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 145. Zentiva Opioid Induced Constipation (OIC) Drugs Product

Table 146. Zentiva Recent Developments/Updates

Table 147. Orifarm A/S Company Information

Table 148. Orifarm A/S Description and Business Overview

Table 149. Orifarm A/S Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 150. Orifarm A/S Opioid Induced Constipation (OIC) Drugs Product

Table 151. Orifarm A/S Recent Developments/Updates

Table 152. Viatris Company Information

Table 153. Viatris Description and Business Overview

Table 154. Viatris Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 155. Viatris Opioid Induced Constipation (OIC) Drugs Product

Table 156. Viatris Recent Developments/Updates

Table 157. Endo International Company Information

Table 158. Endo International Description and Business Overview

Table 159. Endo International Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 160. Endo International Opioid Induced Constipation (OIC) Drugs Product

Table 161. Endo International Recent Developments/Updates

Table 162. Zhengdatianqing Company Information

Table 163. Zhengdatianqing Description and Business Overview

Table 164. Zhengdatianqing Opioid Induced Constipation (OIC) Drugs Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 165. Zhengdatianqing Opioid Induced Constipation (OIC) Drugs Product

Table 166. Zhengdatianqing Recent Developments/Updates

Table 167. Key Raw Materials Lists

Table 168. Raw Materials Key Suppliers Lists

Table 169. Opioid Induced Constipation (OIC) Drugs Distributors List

Table 170. Opioid Induced Constipation (OIC) Drugs Customers List

Table 171. Opioid Induced Constipation (OIC) Drugs Market Trends

Table 172. Opioid Induced Constipation (OIC) Drugs Market Drivers

Table 173. Opioid Induced Constipation (OIC) Drugs Market Challenges

Table 174. Opioid Induced Constipation (OIC) Drugs Market Restraints

Table 175. Research Programs/Design for This Report

Table 176. Key Data Information from Secondary Sources

Table 177. Key Data Information from Primary Sources

Table 178. Authors List of This Report

List of Figures

Figure 1. Product Picture of Opioid Induced Constipation (OIC) Drugs

Figure 2. Global Opioid Induced Constipation (OIC) Drugs Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Opioid Induced Constipation (OIC) Drugs Market Share by Type: 2025 & 2032

Figure 4. Lubiprostone Product Picture

Figure 5. Methyl Naltrexone Bromide Product Picture

Figure 6. Naldemedine Product Picture

Figure 7. Alvimopan Product Picture

Figure 8. Others Product Picture

Figure 9. Global Opioid Induced Constipation (OIC) Drugs Market Value Route of Administration (US$ Million), 2021–2032

Figure 10. Global Opioid Induced Constipation (OIC) Drugs Market Share Route of Administration: 2025 vs 2032

Figure 11. Oral Formulations Product Picture

Figure 12. Injectable Formulations Product Picture

Figure 13. Suppositories / Enemas Product Picture

Figure 14. Other Product Picture

Figure 15. Global Opioid Induced Constipation (OIC) Drugs Market Value Chemical Class (US$ Million), 2021–2032

Figure 16. Global Opioid Induced Constipation (OIC) Drugs Market Share Chemical Class: 2025 vs 2032

Figure 17. Peripheral µ-opioid Receptor Antagonists, Product Picture

Figure 18. Prokinetic Agents Product Picture

Figure 19. Bulk-forming Laxatives Product Picture

Figure 20. Other Product Picture

Figure 21. Small Molecule Product Picture

Figure 22. Peptide Product Picture

Figure 23. Selective 5-HT4 Receptor Agonist Product Picture

Figure 24. Global Opioid Induced Constipation (OIC) Drugs Market Value by Application (US$ Million), 2021–2032

Figure 25. Global Opioid Induced Constipation (OIC) Drugs Market Share by Application: 2025 & 2032

Figure 26. Hospital Pharmacies

Figure 27. Retail Pharmacies

Figure 28. Online Pharmacies

Figure 29. Global Opioid Induced Constipation (OIC) Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 30. Global Opioid Induced Constipation (OIC) Drugs Market Size (US$ Million), 2021–2032

Figure 31. Global Opioid Induced Constipation (OIC) Drugs Sales (K Dose), 2021–2032

Figure 32. Global Opioid Induced Constipation (OIC) Drugs Average Price (USD/Dose), 2021–2032

Figure 33. Opioid Induced Constipation (OIC) Drugs Report Years Considered

Figure 34. Opioid Induced Constipation (OIC) Drugs Sales Share by Manufacturers in 2025

Figure 35. Global Opioid Induced Constipation (OIC) Drugs Revenue Share by Manufacturers in 2025

Figure 36. Top 5 and Top 10 Global Opioid Induced Constipation (OIC) Drugs Players: Market Share by Revenue in Opioid Induced Constipation (OIC) Drugs in 2025

Figure 37. Opioid Induced Constipation (OIC) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 38. Global Opioid Induced Constipation (OIC) Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 39. North America Opioid Induced Constipation (OIC) Drugs Sales Market Share by Country (2021–2032)

Figure 40. North America Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Country (2021–2032)

Figure 41. U.S. Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Canada Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Europe Opioid Induced Constipation (OIC) Drugs Sales Market Share by Country (2021–2032)

Figure 44. Europe Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Country (2021–2032)

Figure 45. Germany Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. France Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. U.K. Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Italy Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Russia Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Asia Pacific Opioid Induced Constipation (OIC) Drugs Sales Market Share by Region (2021–2032)

Figure 51. Asia Pacific Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Region (2021–2032)

Figure 52. China Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. Japan Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. South Korea Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. India Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Australia Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 57. Taiwan Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 58. Indonesia Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 59. Thailand Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 60. Malaysia Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 61. Philippines Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 62. Latin America Opioid Induced Constipation (OIC) Drugs Sales Market Share by Country (2021–2032)

Figure 63. Latin America Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Country (2021–2032)

Figure 64. Mexico Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 65. Brazil Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 66. Argentina Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 67. Middle East and Africa Opioid Induced Constipation (OIC) Drugs Sales Market Share by Country (2021–2032)

Figure 68. Middle East and Africa Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Country (2021–2032)

Figure 69. Turkey Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 70. Saudi Arabia Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 71. U.A.E Opioid Induced Constipation (OIC) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 72. Global Sales Market Share of Opioid Induced Constipation (OIC) Drugs by Type (2021–2032)

Figure 73. Global Revenue Market Share of Opioid Induced Constipation (OIC) Drugs by Type (2021–2032)

Figure 74. Global Opioid Induced Constipation (OIC) Drugs Price (USD/Dose) by Type (2021–2032)

Figure 75. Global Sales Market Share of Opioid Induced Constipation (OIC) Drugs by Application (2021–2032)

Figure 76. Global Revenue Market Share of Opioid Induced Constipation (OIC) Drugs by Application (2021–2032)

Figure 77. Global Opioid Induced Constipation (OIC) Drugs Price (USD/Dose) by Application (2021–2032)

Figure 78. Opioid Induced Constipation (OIC) Drugs Value Chain

Figure 79. Channels of Distribution (Direct Vs Distribution)

Figure 80. Bottom-up and Top-down Approaches for This Report

Figure 81. Data Triangulation

Figure 82. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Opioid Induced Constipation Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030

Global Gastrointestinal OTC Drugs Market Research Report 2024

Global Opioid Withdrawal Treatment Market Insights Forecast to 2030

Global Constipation Treatment Drug Market Research Report 2025

Global Opioid Use Disorder Market Insights Forecast to 2030

Opioid Induced Side Effects Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Opioid Drugs Market Insights Forecast to 2030

Global Chronic Idiopathic Constipation Drugs Market Research Report 2024

Global Opioids Drug Market Research Report 2025

Global Opioid Narcotics Market Research Report 2024

Global Chronic Constipation Treatment Drugs Market Research Report 2024

Global Synthetic Opioids Market Research Report 2024

Opioids Agonist Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global OAB Treatment Market Research Report 2025

Chronic Idiopathic Constipation Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Stool Softeners Market Research Report 2024

Global Prescription Gastrointestinal Drugs Market Research Report 2024

Opioids Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Opioid Use Disorder Treatment Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions